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Abstract
Background: Plasmodium ovale spp. and P. malariae cause illness in endemic regions and returning travellers.
Far less is known about these species than P. falciparum and P. vivax.
Methods: The UK national surveillance data, collected 1987 to 2015, were collated with the International Passenger
Survey and climatic data to determine geographical, temporal and seasonal trends of imported P. ovale spp. and
P. malariae infection.
Results: Of 52,242 notified cases of malaria, 6.04% (3157) were caused by P. ovale spp. and 1.61% (841) by P. malariae;
mortality was 0.03% (1) and 0.12% (1), respectively. Almost all travellers acquired infection in West or East Africa.
Infection rate per travel episode fell fivefold during the study period. The median latency of P. malariae and P. ovale
spp. was 18 and 76 days, respectively; delayed presentation occurred with both species. The latency of P. ovale spp.
infection imported from West Africa was significantly shorter in those arriving in the UK during the West African peak
malarial season compared to those arriving outside it (44 days vs 94 days, p < 0.0001), implying that relapse
synchronises with the period of high malarial transmission. This trend was not seen in P. ovale spp. imported from East
Africa nor in P. malariae.
Conclusion: In West Africa, where malaria transmission is highly seasonal, P. ovale spp. may have evolved to relapse
during the malarial high transmission season. This has public health implications. Deaths are very rare, supporting
current guidelines emphasising outpatient treatment. However, late presentations do occur.
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Background
Plasmodium ovale spp. and P. malariae malaria are less
common than P. falciparum and P. vivax and cause a
milder clinical syndrome than P. falciparum. As a result,
much less is known about them. Although mostly found
in Africa, they are both widely distributed through trop-
ical areas of Asia and Australasia and P. malariae is also
found in the Americas. They are important causes of fe-
brile illness in these regions and in returning travellers.
Their prevalence is often underestimated due to charac-
teristically low parasitaemias and difficulty in distinction
from other malaria species by light microscopy [1].
Recent molecular studies have suggested that these in-
fections are more common than previously thought and
are often mixed with P. falciparum [2–4].
In Africa, P. ovale spp. are the principal relapsing forms
of malaria. P. malariae may also cause long-lasting asymp-
tomatic infection using mechanisms that are not yet
certain [5]. The ability of these species to remain un-
diagnosed for long periods before multiplication and
gametocytaemia occur may hinder malaria eradication
efforts in endemic areas. It also suggests that they are
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likely to increase as a proportion of malaria as control
efforts improve.
Both species are also important causes of febrile illness
in returning travellers because, unlike P. falciparum,
they may present months or even years after return from
an endemic region [5, 6]. At this point, patients and
their physicians are less likely to link a febrile illness
with travel, resulting in delayed or missed diagnosis [7].
In recent years, P. ovale has been distinguished into
two separate species, P. ovale curtisi and P. ovale walli-
keri. These two species, though morphologically identi-
cal by light microscopy, are genetically distinct and
non-recombinant. Both species are thought to form hyp-
nozoites and to be sympatric throughout their geograph-
ical range [8]. It is unclear whether clinical disease
differs between the two species [9, 10].
This study, which is the largest series of P. ovale spp.
and P. malariae infections presented to date, aims to an-
swer three sets of questions. Firstly, how do these spe-
cies present in non-endemic countries and what are the
travel and temporal trends? Secondly, is there any differ-
ence in seasonal latency in P. ovale spp. infections, as is
seen in P. vivax malaria, the other relapsing malarial
species? Thirdly, using a subset of isolates speciated to
either P. ovale curtisi or P. ovale wallikeri, is there any
difference in latency between the two?
Methods
The Public Health England Malarial Reference Labora-
tory (PHE MRL), formerly the Health Protection Agency
Malarial Reference Laboratory, has been systematically
collecting malaria data in the UK since 1987. This repre-
sents one of the largest and most complete continuous
series on imported malaria worldwide. The process has
been previously described, and in order to maintain
comparable data over time, methodology has remained
largely unchanged since its inception [11]. Inclusion is
dependent on parasitological diagnosis by blood film or
molecular methods undertaken in a specialist malaria la-
boratory. Passive surveillance is conducted by statutory
notification of all cases from UK hospitals. UK laborator-
ies also send blood films for verification of diagnosis by
light microscopy and polymerase chain reaction. Data
from reporting hospitals are collected on a standardised
form; this includes age, sex, countries visited, reason for
and dates of travel. A capture-recapture study estimates
a national case ascertainment rate of 56% [11].
All cases of P. ovale spp. and P. malariae reported be-
tween January 1, 1987, and December 31, 2015, were
identified. Once cleaned, the data were analysed for geo-
graphic, seasonal and temporal trends. Countries were
grouped as per United Nations’ regions. This large data-
set includes some cases considered in two previous stud-
ies examining latency and prophylaxis use [5, 6].
The study set out to identify any seasonal trends in la-
tency, in particular whether there was evidence of a
tendency for P. ovale spp. to relapse during the period of
peak malaria transmission in region of acquisition. The
period of high malaria transmission in West Africa (the
malaria season) was defined as August to November using
data from studies conducted to inform seasonal malarial
chemoprevention [12–15]. Although malaria is less sea-
sonal in East Africa, the malaria season was designated as
April to July inclusive. The latent period was defined as
time between arrival in the UK and onset of symptoms.
Data on travel were collated with the International Pas-
senger Survey (IPS). This continuous survey uses 250,000
interviews per year from travellers at UK sea, land and air
ports to estimate travel to and from the UK to individual
countries [16]. Pertinent data were available from 1993
onwards. These data were used as a denominator to estab-
lish attack rates and change in incidence of infection in
travellers over time. In contrast to the methodology used
for primary collection of the malaria data, which aims to
be complete, the IPS is a representative sampling method-
ology. The two databases were not combined.
Prior to 2003, light microscopy alone was used for spe-
cies identification. Conventional PCR to detect species
was introduced in 2003. Since 2013, some P. ovale spp.
samples have been further speciated to P. ovale curtisi
and P. ovale wallikeri using molecular methods. As pre-
viously described [6], P. ovale spp. infections are first
confirmed by conventional amplification of the small
subunit ribosomal RNA genes [17, 18]. The two species
are then discriminated by conventional amplification at
the potra locus and quantitative real-time PCR amplifi-
cation of the porbp2 locus [19]. These data were further
analysed to compare geographic, seasonal and temporal
trends between these two species.
Data were entered using dBase and analysed using STATA
14. Simple proportions were calculated together with rates
of infection. Wilcoxon rank-sum was used to establish sig-
nificance for skewed continuous data, mainly latency.
This study analyses routine surveillance data collected,
analysed and published as the legal obligation of PHE
under Regulation 3 of the Health Service Regulations
2002. Such analysis does not have separate ethics approval
but is covered under existing regulatory frameworks and
responsibilities. No extra data requiring separate ethics ap-
proval were collected as part of this study. Data from indi-
vidual patients were pseudo-anonymized before analysis.
Results
Between January 1, 1987, and December 31, 2015,
52,242 cases of malaria were notified to the MRL: 59.7%
(31,191) cases were male and 35% (18,273) female. Sex
was not documented in 5.3% (2778) cases. The median
age was 32 years (interquartile (IQ) range 22–45).
Nabarro et al. BMC Medicine          (2018) 16:218 Page 2 of 8
P. falciparum was the most common imported species
(34,455, 66.0% of notifications), followed by P. vivax
(13,070, 25.0%), P. ovale spp. (3157, 6.0%), P. malariae
(841, 1.6%) and P. knowlesi (1, 0.002%). There were 588
(1.1%) mixed species infection and 162 cases (0.3%) where
the species was not documented. Figure 1 shows the spe-
ciated cases of malaria notified each year since 1987.
When proportions of cases before the year 2000 were
compared with those after 2000, the proportion of P. vivax
had fallen by 44.5% whilst the proportion of P. falciparum,
P. malariae and P. ovale spp. had risen by 32%, 41% and
5.7%, respectively.
Demographic and clinical features
P. ovale spp.
Three thousand one hundred fifty-seven cases of P. ovale
spp. were notified over this period: 65.2% (2058) were
male and 30% (947) female (4.8%, 152 sex not docu-
mented) with a median age of 28 (IQ range 21–38). In
86.7% (2738) cases, the region of acquisition was docu-
mented. Of these, 98.2% (2689) cases of P. ovale spp. were
acquired in Africa, mostly from West (58.4%, 1599) and
East Africa (24.6%, 675) but also from Central (5.5%, 150),
North (0.7%, 20) and South (1.2%, 32) Africa. Two hun-
dred thirteen people (7.8%) had travelled to more than
one region in Africa, so the region of malaria acquisition
was unclear. The commonest countries where infection
was acquired were Nigeria (33.3%, 911), Ghana (12.2%,
335), Uganda (7.3%, 199), Kenya (6.1%, 167), and Sierra
Leone (5.6%, 154). Most people acquiring infection in
West Africa were visiting friends and family (87.3%, 577)
whilst those acquiring infection in East Africa were pre-
dominantly tourists (55.5%, 142, p < 0.001). The mortality
rate was 0.03%(1); the only recorded death occurred in a
51-year-old woman who died of splenic rupture, a direct
complication of malaria but one which occasionally occurs
with all species. In contrast to P. vivax, where deaths are
heavily weighted to older patients [20], no deaths were re-
ported in the 135 (4.4%) patients aged more than 60 years.
The median latency from arrival was 76 days for P.
ovale spp. (range − 53 to 3167 days), compared to 4 days
for P. falciparum and 67 days for P. vivax. Delayed pres-
entation, meaning presentation beyond 90 days, oc-
curred in 23.4% (738) cases of P. ovale spp. with 2.7%
(85) cases presenting more than a year after arrival in
the UK. In comparison, 0.6% (197) of P. falciparum
cases presented more than 90 days after arrival in the
UK and 0.1% (42) after more than a year: 22.0% (2879)
of P. vivax cases presented more than 90 days after ar-
rival and 2.1% (269) after more than a year.
P. malariae
Eight hundred forty-one cases of P. malariae were noti-
fied over this period; 63.7% (536) were male, and 31.4%
(264) were female (4.9%, 41 sex not documented) with a
median age of 29 (IQ range 20–40). In 86.0% (723)
cases, the region of acquisition was documented. 98.5%
(712) infections were acquired in Africa, mostly from
West (55.9%, 404) and East Africa (28.9%, 209) but also
from Central (6.5%, 47), North (1.1%, 8) and South
Fig. 1 Cases of malaria by species notified each year, 1987–2015
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Africa (0.4%, 3). Forty-one people (5.7%) had travelled to
more than one region in Africa, so the region of malaria
acquisition was unclear. The commonest countries of
acquisition were similar to those of P. ovale spp.: Nigeria
(30.7%, 222), Ghana (12.6%, 91), Uganda (10.9%, 79),
Kenya (8.4%, 61) and Sierra Leone (4.7%, 34). Most
people acquiring infection in West Africa were visiting
friends and family (91.2%, 175) whilst those acquiring in-
fection in East Africa were evenly split between those
visiting friends and family (48.8%, 41) and tourists
(51.2%, 43, p< 0.001). The mortality rate was 0.12% (1). The
single death was that of a 48-year-old man who died of a
hospital-acquired pneumonia, a complication of hospital
admission rather than a recognised direct complication of
P. malariae malarial infection. There were no deaths re-
ported in 29 patients (3.5%) aged more than 60 years.
As previously reported [5], the median latency of P.
malariae was 18 days (IQ range 3–46, range − 51 to
1123 days). 4.2% (35) cases presented more than 90 days
after arrival in the UK, and 0.2% (2) cases presented
more than a year after arrival.
Rates of infection compared to travel data—temporal trends
Between 1993 and 2015, traveller numbers to West
Africa increased by 380.6% whilst traveller numbers to
East Africa increased by 221.9%. In West Africa, total
attack rates of P. ovale spp. and P. malariae fell 4.8-fold
from 0.62 to 0.13 per thousand trips. In East Africa, total
attack rates fell from 0.19 to 0.038 per 1000 travel epi-
sodes, a fivefold reduction (Fig. 2).
Latency of P. ovale spp. cases by malaria season
Most patients with P. ovale spp. infection arrive in the
UK between August and October but develop symptoms
between September and January (Fig. 3). The overall me-
dian latent period was 76 days (IQ range 19–158 days,
range − 53 to 3617 days), similar to that of P. vivax
(67 days, (IQ range 9–211 days, range − 30 to 2195 days),
which also has a hypnozoite state.
In patients who acquired infection in West Africa, there
was a significant difference in latency between patients
who presented with P. ovale spp. infection during the
West African malaria season (44 days) compared to those
presenting outside this season (94 days, p < 0.0001). There
was no evidence of variation in latency by month of ar-
rival. In patients who had acquired malaria in East Africa,
there was no difference in latency between those present-
ing with symptoms during or outside the malaria season
(73 days vs 87 days, p = 0.58) (Fig. 4).
For 243 patients, P. ovale spp. speciation data was
available. 53.9% (131) patients had P. ovale wallikeri
whilst 46.1% (112) had P. ovale curtisi. There were no
Fig. 2 Incidence of P. ovale spp. and P. malariae per travel episode 1993–2015
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cases shown to harbour both P. ovale spp. in our sample
set. 65.6%(158) samples were from West Africa; 51.3%
(81) were P. ovale wallikeri and 48.7% (77) were P. ovale
curtisi. 22.4%(54) were from East Africa; 61.1% (33) were
P. ovale wallikeri and 38.9% (21) were P. ovale curtisi.
11.5% (28) samples were from people who had travelled
elsewhere in Africa. One sample (0.4%) was from a trav-
eller to Southeast Asia, and 2 (0.85%) had unknown
travel histories. P. ovale curtisi had a latent period of
86 days (IQ range 15–187 days, range − 3 to 538 days),
significantly longer than that of P. ovale wallikeri at
29 days (IQ range 5–92 days, range − 8 to 558 days,
p = 0.0014). The latent period in patients presenting with
P. ovale wallikeri during the West African malaria season
was significantly shorter at 11 days compared to those
presenting outside this season (54 days, p = 0.0011). A
similar trend was seen in P. ovale curtisi, but it did not
achieve significance, in the context of small numbers
(88 vs 41 days; p = 0.40) (Table 1).
Discussion
To our knowledge, this is the largest study in the literature
to date of imported P. ovale spp. and P. malariae infec-
tion. It extends previous findings from the UK MRL [5, 6,
20]; the scale and duration of this study allows for robust
clinical and public health findings. A striking finding is
that P. ovale spp. infection tends to present during the
West African high transmission malaria season, suggest-
ing latency correlates with the peak transmission season
in region of acquisition. Both species are uncommon
causes of malaria in the UK, and almost all cases are
imported from Africa. Incidence per travel episode is fall-
ing, probably due to improved malaria control in endemic
areas, but on the background of steadily rising travel to
malaria-endemic Africa, they are likely to remain an im-
portant if relatively rare cause of imported febrile illness
for the foreseeable future. Although delayed presentation
does occur in both P. ovale spp. and P. malariae infection,
these data suggest that substantially delayed presentation
Fig. 3 P. ovale spp. infection categorised by month of the UK arrival and month of onset of symptoms
Fig. 4 P. ovale spp. latency between arrival in the UK and onset of symptoms by month of symptom onset with relation to malaria season in
West Africa
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is relatively rare. The very low mortality for both species
in the context of a high-income setting is confirmed.
The most striking finding is the seasonal nature of P.
ovale spp. latency between leaving West Africa and onset
of symptoms. The latent period is significantly shorter in
those presenting from West Africa with symptoms in Eur-
ope during the West African malaria season than outside
it. Most delayed cases of P. ovale spp. malaria are likely to
represent hypnozoite relapse, and this suggests that in
West Africa, where malaria transmission is usually highly
seasonal, relapse synchronises with the malaria season
wherever it is acquired. This is of potential evolutionary
benefit as it maximises the chance of parasite transmission
to mosquito and subsequent human host. Relapsing forms
of malaria are especially well adapted to getting through
periods of lower transmission.
There are also public health implications of this find-
ing; the peak in P. ovale spp. infection during the West
African malaria season is likely to be larger and made up
of increased transmission, but also increased relapse.
Targeting transmission control measures during the mal-
aria season may have a smaller effect on cases than
would be expected if relapse happened randomly
through the year. Conversely, targeting anti-hypnozoite
interventions just before the West African malaria sea-
son may have a larger effect than would be predicted if
randomness of relapse is assumed. The use of seasonal
malaria chemoprevention, which targets malaria blood
stages, may have a greater impact on P. ovale malaria be-
cause of this temporality.
A similar but stronger trend in latency has previously
been reported in P. vivax which also has a hypnozoite
stage. In the UK, P. vivax is predominantly acquired in
the Indian sub-continent. Most patients present with P.
vivax during the summer months in the UK, which coin-
cides with the malaria season in the Indian sub-continent
[21, 22]. The latent period is significantly shorter in people
arriving in the UK during this period [20]. There has been
speculation that P. vivax reactivation is due to increased
ambient temperatures in the UK. However, the compar-
able trend that we have observed with P. ovale spp. lends
weight to the hypothesis that relapse occurs in the malar-
ial season. Thus, there is evidence that each malaria spe-
cies with hypnozoite stages relapses during the peak
malaria transmission season in their region of acquisition,
if transmission in that area is highly seasonal.
The clear season-dependent difference in latency for
P. ovale spp. infection imported from West Africa was
not observed in cases imported from East Africa. The
seasonality of malaria transmission is generally much
less pronounced in East Africa, one reason seasonal mal-
aria chemoprevention is less appropriate in that area
[13]. As 98% of P. ovale spp. imported to the UK comes
from Africa, it was not possible to interpret this trend
for other regions of the world.
P. ovale curtisi and P. ovale wallikeri have previously
been found to be sympatric in West and East Africa and
are proposed to have significantly different latent periods
[6, 9]. This is confirmed in the current larger study where
median latencies were estimated at 86 and 23 days re-
spectively. For P. ovale wallikeri, the latent period was sig-
nificantly shorter in those presenting with symptoms
during the West African malaria season than outside it
(11 vs 54 days). A similar trend was visible in P. ovale cur-
tisi but did not reach significance, possibly due to small
numbers; the two species were not differentiated until re-
cently so the numbers of cases available for analysis were
few. Alternatively, it may be that the overall correlation
seen with P. ovale spp. is driven solely by P. ovale wallikeri
and that this seasonal relationship does not exist for P.
ovale curtisi. Although the hypnozoite state has not been
formally identified in either of these species, these data
suggest that it exists and that hypnozoites are pro-
grammed to activate in the season when they are most
likely to be transmitted to a mosquito vector.
Interestingly, the relative abundance of P. ovale spp.
among travellers compared to P. malariae is the reverse
of reports from cross-sectional studies in the field, where
infections with P. malariae are more likely to be ob-
served. This interesting discrepancy may be due to a
higher mosquito transmission capacity for ovale malaria,
and a longer duration of infection for P. malariae [10].
As in other studies, mortality from both P. ovale spp. and
P. malariae infection is low [23, 24]. These large numbers
give confidence in supporting the UK and other inter-
national guidance that these infections can usually be man-
aged in outpatient settings unless the patient has significant
comorbidities or is unable to tolerate oral therapy [25]. In
contrast to P. falciparum and P. vivax, older age was not
associated with increased mortality in these imported infec-
tions [20, 26]. However, the long delay in some cases be-
tween leaving an endemic area and development of illness
presents a diagnostic challenge. It is essential that clinicians
take an extended travel history and consider malaria in
2 years after people return from Africa.
Table 1 Latency in P. ovale spp. acquired in West Africa,
malarial season vs non-malarial season
Latency
(days)
Latency in
malaria
season (days)
Latency in
non-malaria
season (days)
Significance
(p)
P. ovale
(n = 1599)
76 44 94 < 0.0001
P. ovale curtisi
(n = 77)
80.5 41 88 0.4
P. ovale wallikeri
(n = 81)
17.5 11 54 0.0011
Significance (p) 0.0073
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The strength of this study lies in its large size and use
of national surveillance data, collected prospectively with
little methodological change, over a period of 29 years.
As these species are relatively much less frequent causes
of imported malaria, only large datasets can explore
them. Because the UK is a non-endemic area, we are
able to draw conclusions on latent periods and seasonal
trends as the possibility of reinfection can be excluded.
These trends would not be possible to establish in en-
demic zones due to continuous exposure and the possi-
bility of reinfection.
There are a number of limitations, common to all stud-
ies using national observational data. The database relies
on passive case detection and, inevitably, will underesti-
mate the numbers of imported cases although capture-re-
capture data suggest the majority are identified. It does
not capture data on the UK residents taken ill and treated
for malaria whilst travelling abroad. We defined the latent
period as time from arrival in the UK to onset of symp-
toms. This definition underestimates the true latent period
as it is unlikely travellers are infected on the day that they
left an endemic area. However, this caveat is very unlikely
to explain the temporal trend of P. ovale spp. cases. Unfor-
tunately, duration of individual travel episodes was not
collected in a sufficiently uniform way to be able to use it
reliably in analysis.
Although it has been a routine to distinguish P. ovale
curtisi from P. ovale wallikeri in samples of P. ovale re-
ceived in the MRL since 2013, limited speciation data was
available from samples before this period. There is in-
creasing evidence, from this and other studies, that these
two species behave differently regarding latency. We were
only able to analyse this in a small subset of samples.
Conclusion
P. ovale spp. and P. malariae are unusual causes of
imported malaria to the UK and are almost always acquired
in Africa. Incidence per travel episode is falling, and mortal-
ity rates are very low. Whilst P. malariae usually presents
clinically within the first 28 days after return, the latent
period of P. ovale spp. is significantly longer at 67 days. In
travellers returning from West Africa, there is a significant
difference in latency in patients presenting with symptoms
during the malaria season in the region from which they
travelled compared to those presenting outside this season.
This is similar to the trend seen in imported P. vivax and
suggests that, in areas where malaria transmission is highly
seasonal, hypnozoites from both species activate during the
season when they are most likely to be transmitted to a
mosquito vector and subsequent human host.
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